Mrna vaccine for advanced ebv-related cancers
Treatments studied
Part of Cancer, Infections clinical trials.
This study tests a new mRNA vaccine that helps your immune system fight cancer cells linked to the Epstein-Barr virus. It may be an option for people with advanced EBV-positive cancers that have not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You need to have a type of cancer that is positive for Epstein-Barr virus (EBV), such as nasopharyngeal carcinoma, NK/T-cell lymphoma, or gastric cancer, and it must have worsened after at least two standard treatments.
- You should be able to take care of yourself and be out of bed more than half of the day.
- Your vital organs (like liver, kidneys, heart) must be working well enough.
- You must not be pregnant or breastfeeding.
- You must not have other serious medical conditions, such as uncontrolled heart problems, active infections like HIV or hepatitis, or a history of certain lung diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new mRNA-based immunotherapy for diseases caused by the Epstein-Barr virus (EBV), such as certain cancers and conditions after a stem cell transplant. The treatment aims to help your immune system fight the virus and the disease.
This trial tests an investigational mRNA vaccine (WGc-043) that aims to help your immune system fight EBV-positive lymphoma cells. If you have tried standard treatments and your lymphoma is still active, this vaccine might offer a new option.
This trial tests a new mRNA vaccine that targets the Epstein-Barr virus (EBV) in people with HIV-related lymphoma. The goal is to see if the vaccine can help the immune system fight the cancer, especially for those whose lymphoma has not fully responded to standard treatments.
This trial tests an experimental mRNA vaccine (mRNA-1189) to see if it can prevent Epstein-Barr virus (EBV) infection. It is for healthy adults 18 to 30 years old.
This trial tests a new mRNA vaccine designed to protect against the Epstein-Barr virus, which is a common virus that can cause illnesses like mono. It is for healthy young adults to see if the vaccine is safe and triggers a good immune response.
This trial tests a combination of a drug that reactivates the Epstein-Barr virus (EBV) in the body plus an immunotherapy drug (PD-1 antibody) for people with nasopharyngeal cancer that has returned or spread. The goal is to see if this combination can help the immune system fight the cancer more effectively.
Hear when a new EBV-associated Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.